Maternal Death — Reducing Racial Disparities in Severe Maternal Morbidity
Citation(s)
Bernet P, Gumus G, Vishwasrao S Maternal Mortality and Public Health Programs: Evidence from Florida. Milbank Q. 2020 Mar;98(1):150-171. doi: 10.1111/1468-0009.12442. Epub 2020 Jan 14.
Burns JJ, Livingston R, Amin R The Proximity of Spatial Clusters of Low Birth Weight and Risk Factors: Defining a Neighborhood for Focused Interventions. Matern Child Health J. 2020 Aug;24(8):1065-1072. doi: 10.1007/s10995-020-02946-y.
Cesar JA, Camerini AV, Paulitsch RG, Terlan RJ Non-performance of serological tests for syphilis during prenatal care: prevalence and associated factors. Rev Bras Epidemiol. 2020 Feb 21;23:e200012. doi: 10.1590/1980-549720200012. eCollection 2020. English, Portuguese.
Fernandes KG, Sousa MH, Cecatti JG Skin Color and Maternal Near Miss: Exploring a Demographic and Health Survey in Brazil. Rev Bras Ginecol Obstet. 2017 May;39(5):209-216. doi: 10.1055/s-0037-1603498. Epub 2017 May 22.
Gillespie SL, Christian LM, Alston AD, Salsberry PJ Childhood stress and birth timing among African American women: Cortisol as biological mediator. Psychoneuroendocrinology. 2017 Oct;84:32-41. doi: 10.1016/j.psyneuen.2017.06.009. Epub 2017 Jun 15.
Hans SL, Edwards RC, Zhang Y Randomized Controlled Trial of Doula-Home-Visiting Services: Impact on Maternal and Infant Health. Matern Child Health J. 2018 Oct;22(Suppl 1):105-113. doi: 10.1007/s10995-018-2537-7. Erratum In: Matern Child Health J. 2018 Aug 20;:
Howell EA, Egorova NN, Balbierz A, Zeitlin J, Hebert PL Site of delivery contribution to black-white severe maternal morbidity disparity. Am J Obstet Gynecol. 2016 Aug;215(2):143-52. doi: 10.1016/j.ajog.2016.05.007. Epub 2016 May 12.
Lundeen EA, Park S, Woo Baidal JA, Sharma AJ, Blanck HM Sugar-Sweetened Beverage Intake Among Pregnant and Non-pregnant Women of Reproductive Age. Matern Child Health J. 2020 Jun;24(6):709-717. doi: 10.1007/s10995-020-02918-2.
Murugappan, G , Li, S., Lathi, R., Baker, V., & Eisenberg, M. (2018). Increased risk of maternal morbidity in infertile women: Analysis of US claims data. Fertility and Sterility, 110(4). doi:10.1016/j.fertnstert.2018.07.046
Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010 Feb;24(2):104-10. doi: 10.1038/jhh.2009.45. Epub 2009 Jun 11.
Small MJ, James AH, Kershaw T, Thames B, Gunatilake R, Brown H Near-miss maternal mortality: cardiac dysfunction as the principal cause of obstetric intensive care unit admissions. Obstet Gynecol. 2012 Feb;119(2 Pt 1):250-5. doi: 10.1097/AOG.0b013e31824265c7.
Thomas MP, Ammann G, Brazier E, Noyes P, Maybank A Doula Services Within a Healthy Start Program: Increasing Access for an Underserved Population. Matern Child Health J. 2017 Dec;21(Suppl 1):59-64. doi: 10.1007/s10995-017-2402-0.
Zhou X, McQueen DB, Schufreider A, Lee SM, Uhler ML, Feinberg EC Black recipients of oocyte donation experience lower live birth rates compared with White recipients. Reprod Biomed Online. 2020 May;40(5):668-673. doi: 10.1016/j.rbmo.2020.01.008. Epub 2020 Jan 23.
Reducing Racial Disparities in SMM: Assessing the Integration of Maternal Safety Bundles and Community Based Doulas to Improve Outcomes for Black Women
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.